Healthcare
Wende Hutton
General Partner / West Coast
Since 2004
Wende identifies, builds and invests in companies that change medicine by bringing novel drugs, technologies and devices to market. She has partnered with founders to deliver more than a dozen of those innovations to patients. She started her venture career as a General Partner at Mayfield. She previously held senior marketing roles at GenPharm and Nellcor. Wende holds an A.B. in human biology from Stanford University and an M.B.A. from Harvard Business School.
Wende in 5
Travel: City sights followed by outdoor adventure days – perfect combo
Origins: Stints in Asia & Europe but I never leave my native Bay Area for long
Giving: Global health & preserving the environment
Sport: Hiking, biking, skiing, sailing & the list goes on…
Dream Job: Field biologist working on broad scale conservation
Investments
Previous
-
Alsius Corporation
Acquired by Zoll -
Apieron
Acquired by Aerocrine -
BiPar Sciences, Inc.
Acquired by Sanofi-Aventis -
Calibra Medical
Acquired by LifeScan / Johnson & Johnson -
Chimerix
IPO -
Dermira
IPO -
Labrys Biologics
Acquired by Teva Pharmaceutical -
Northstar Neuroscience
IPO -
Transcend Medical
Acquired by Alcon / Novartis
Latest
FierceBiotech: Better Therapeutics adds digital treatment into Glooko’s diabetes management platform
SF Business Times: Global vision for women's health lands Antiva $31M
Reconvening for a virtual Women Who Venture gathering
Fierce Biotech: Qlaris, armed with $25M round, pushes new glaucoma drug into clinic
FierceBiotech: Glooko raises $30M to expand digital diabetes efforts
Annual Women Who Venture Gathering 2020
FierceBiotech: Hyalex snags medtech vet Mark Roby as R&D Chief
EY Pulse on the Industry Report: Wende Hutton offers a perspective on the today's medtech investment climate
WoVen Podcast: Crafting success (and balance) in venture - A conversation with Wende Hutton
FierceBiotech: Glooko makes its management app free to any person with diabetes
BioCentury: Wende Hutton on mapping microbiome manufacturing
Business Insider: Wende Hutton and top VCs give their best 2019 predictions for healthcare
SF Business Times: Antiva CEO draws on personal experience to fuel drug development
BioCentury: Sweet switch - Glooko & Novo Nordisk A/S partner on diabetes monitoring app
STAT News: Antiva tried to drum up interest for a much-needed drug. Many men didn’t get it
Endpoints: Virtual biotech Antiva sets out on a big R&D quest, armed with a $22 million round for an HPV therapy
Spotlight on Wende Hutton’s 25 years in venture capital
Business Insider: Wende Hutton shares her best career advice
C&EN: Investment flows at J.P. Morgan Healthcare Conference
Endpoints News: Six top biotech VCs take a look at the latest trends, and offer their thoughts on 2018
CNBC: 11 women who prove that health tech investing isn’t a boys’ club
Fierce Biotech: Canaan unveils $800 million fund for fresh wave of biotech bets
TechCrunch: Diabetes management platform Glooko raises $35 million
BioTech Nation Podcast: Women in biotech venture capital
Biotech NOW: Invest in diversity to drive innovation
Fierce Biotech: “Synthetic cartilage” startup raises Hyalex reels in $16 million
Wende in 5
Travel: City sights followed by outdoor adventure days – perfect combo
Origins: Stints in Asia & Europe but I never leave my native Bay Area for long
Giving: Global health & preserving the environment
Sport: Hiking, biking, skiing, sailing & the list goes on…
Dream Job: Field biologist working on broad scale conservation